What’s the point of neuropsychological testing for Alzheimer's disease or dementia if there’s no cure? No new protection indicators were observed with ongoing lecanemab treatment. After the first six months, ARIA rates were similar to rates seen with placebo, van Dyck and colleagues reported. See collaborations Collaborations that electric power https://earley975whu6.blogoxo.com/profile